INNT is due for a breakout

INN-202 is currently the only drug candidate entering into Phase 3 trials. Larazotide is shown to be effective with hundreds of patients. The company has drug candidates also for NASH, Crohn's, and ulcerative colitis in addition to more than 150 patents. They recently hired somebody with successful Phase 3 experience on other drugs.